drugset

drugset / Trial / NCT00563316

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

NCT00563316 ↗

Phase 1 Completed 28 enrolled Amgen

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.

Timeline

Start: 2008-03
Primary completion: 2009-03
Completion: 2010-06

Publications

Background Yang BB, Wu CY, Chen E, Infante JR, Chen A, Gao B, Smith B, Litten J, Kennecke H. Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. Clin Pharmacol Drug Dev. 2013 Jul;2(3):205-12. doi: 10.1002/cpdd.35. Epub 2013 May 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	180 mg/m2	Intravenous
Subject	Panitumumab	Monoclonal antibody	6 mg/kg	Intravenous

Indications